

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

**VOLUNTARY ANNOUNCEMENT
NEW DRUG APPLICATION FOR DORZAGLIATIN ACCEPTED IN CHINA
BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Hua Medicine (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Company’s Board of Directors (the “**Board**”) today announced that the new drug application (“**NDA**”) submitted by the Company’s innovative, first-in-class diabetes drug dorzagliatin has been formally accepted by the China National Medical Products Administration (“**NMPA**”). Dorzagliatin is the first glucokinase activator (“**GKA**”) diabetes treatment drug to submit an NDA in the world, and is expected to launch in China first.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that the Company will be able to develop, or ultimately market, dorzagliatin successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board

Dr. Li Chen

Chief Executive Officer and Executive Director

Shanghai, April 23, 2021

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.